Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III Sells 20,000 Shares

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00. Following the transaction, the director now owns 1,071,974 shares of the company’s stock, valued at approximately $7,107,187.62. The trade was a 1.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Pulmonx Price Performance

Shares of NASDAQ LUNG opened at $6.30 on Thursday. The firm has a market capitalization of $248.79 million, a P/E ratio of -4.29 and a beta of 0.68. The firm’s 50-day moving average price is $6.96 and its 200-day moving average price is $7.08. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period in the previous year, the company posted ($0.39) EPS. Equities research analysts anticipate that Pulmonx Co. will post -1.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pulmonx

A number of institutional investors have recently modified their holdings of LUNG. 272 Capital LP acquired a new stake in Pulmonx in the 3rd quarter valued at $25,000. nVerses Capital LLC bought a new position in shares of Pulmonx in the third quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Pulmonx during the second quarter valued at about $37,000. Hsbc Holdings PLC bought a new stake in shares of Pulmonx during the second quarter worth about $93,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Pulmonx in the 2nd quarter worth about $102,000. 91.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LUNG shares. Stifel Nicolaus lowered their target price on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Canaccord Genuity Group lifted their price objective on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Wells Fargo & Company cut their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.67.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.